Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Trial Profile

Evaluating in Vivo AZA Incorporation in Mononuclear Cells Following Vidaza or CC486

Not yet recruiting
Phase of Trial: Phase II

Latest Information Update: 16 Apr 2018

At a glance

  • Drugs Azacitidine (Primary) ; Azacitidine
  • Indications Acute myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Pharmacokinetics
  • Sponsors Celgene Corporation
  • Most Recent Events

    • 16 Apr 2018 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top